

# **Local Medicines Formulary**

The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH) is a leading orthopaedic centre of excellence. A specialist hospital with a reputation for innovation, the Trust provides a comprehensive range of musculoskeletal (bone, joint and tissue) surgical, medical and rehabilitation services; locally, regionally and nationally. The organisation is a single site hospital based in Oswestry, Shropshire, close to the border with Wales. As such, the Trust serves the people of both England and Wales, as well as acting as a national healthcare provider.

The trust has a limited formulary in recognition that it provides specialist services to patients from a large geographical area. Patients admitted to the trust currently taking medicines not included in the formulary will have their normal pre-admission medicines continued where appropriate. Some medicines included in the Trust formulary are available on a limited basis due to funding decisions made by local commissioners.

The medicines in the local formulary are presented according to the BNF classification. The BNF should be consulted for product information and prescribing guidelines. The content of this formulary will be under continual review and update. Drugs chosen to be included in the formulary have been made on the basis of clinical efficacy, safety and cost effectiveness.

The formulary includes medicines with a positive NICE technology appraisal if clinically appropriate and relevant to the services provided by the trust.

The intention of the formulary is not to limit clinical freedom but to guide in the initial choice of medicines.

#### **Gastro-intestinal system**

Lansoprazole	2 <sup>nd</sup> choice proton pump inhibitor	BNF 1.3.5
Omeprazole	1 <sup>st</sup> choice proton pump inhibitor	BNF 1.3.5
Prucalopride	NICE TAG 211	BNF 1.6.7

#### **Cardiovascular system**

Enoxaparin	As recommended by Trust Venous thromboembolism policy	BNF 2.8.1
Apixaban	NICE TAG 245  Apixaban is a treatment option for the prevention of venous thromboembolism, for patients having hip or knee replacement, <b>only</b> in patients who prior to admission were taking apixaban for another indication, e.g. atrial fibrillation.	BNF 2.8.2

Dabigatran	NICE TAG157 As recommended by Trust Venous thromboembolism policy  NICE TAG 249 Adopted as per the Shropshire and Staffordshire Heart and Stroke Network pathway.	BNF 2.8.2
Rivaroxaban	NICE TAG 170 Rivaroxaban is a treatment option for the prevention of venous thromboembolism for patients having hip or knee replacement, <b>only</b> in patients who prior to admission were taking rivaroxaban for another indication, e.g. atrial fibrillation.  NICE TAG 256 Adopted as per the Shropshire and Staffordshire Heart and Stroke Network pathway.  NICE TAG 261 Adopted as per the Shropshire and Staffordshire Heart and Stroke Network pathway.	BNF 2.8.2
Clopidogrel	NICE TAG 210	BNF 2.9
Dipyridamole	NICE TAG 210	BNF 2.9

## **Central nervous system**

Paracetamol IV	BNF 4.7.1
BuTrans <sup>®</sup> Patches	BNF 4.7.2
Pregabalin	BNF 4.7.3

### **Infections**

The Trust uses the "Antibiotics for Adults in Shropshire Hospitals" published separately.

## **Endocrine system**

Raloxifene	NICE TAG160 NICE TAG161	BNF 6.4.1
Parathyroid Hormone		BNF 6.6.1
Teriparatide	NICE TAG161	BNF 6.6.1
Alendronate	NICE TAG160 NICE TAG161	BNF 6.6.2
Denosumab	For prevention of Osteoporotic Fractures in Postmenopausal Women only NICE TAG 204	BNF 6.6.2
Etidronate	NICE TAG160 NICE TAG161	BNF 6.6.2
Ibandronic Acid		BNF 6.6.2
Risedronate	NICE TAG160 NICE TAG161	BNF 6.6.2
Strontium ranelate	NICE TAG160 NICE TAG161	BNF 6.6.2

## Obstetrics, gynaecology and urinary tract disorders

Oxybutynin tablets		BNF 7.4.2
Oxybutynin patches (Kentera®)	Restricted to prescribing by consultants for short term use only in spinal injuries patients undergoing bladder endoscopic procedures	BNF 7.4.2
Solifenacin	Approved as 3 <sup>rd</sup> line treatment after oxybutynin and tolterodine orally.	BNF 7.4.2
Tolterodine		BNF 7.4.2
Sildenafil	For erectile dysfunction in patients with spinal cord injury	BNF 7.4.5
Tadalafil	For erectile dysfunction in patients with spinal cord injury	BNF 7.4.5

### **Nutrition and blood**

Calceos	BNF 9.6.4
---------	-----------

## Musculoskeletal and joint diseases

	NITOE TAG 405	DNE 40 4 2
Abatacept	NICE TAG 195	BNF 10.1.3
	NICE TAG 234	
Adalimumab	NICE TAG 130	BNF 10.1.3
	NICE TAG 143	
	NICE TAG 195	
	NICE TAG 199	
Certolozumab pegol	NICE TAG 186	BNF 10.1.3
Etanercept	NICE TAG 130	BNF 10.1.3
	NICE TAG 143	
	NICE TAG 195	
	NICE TAG 199	
Golimumab	NICE TAG 220	BNF 10.1.3
	NICE TAG 225	
	NICE TAG 233	
Infliximab	NICE TAG 130	BNF 10.1.3
	NICE TAG 143	
	NICE TAG 195	
	NICE TAG 199	
Rituximab	NICE TAG 195	BNF 10.1.3
Tocilizumab	NICE TAG 247	BNF 10.1.3
Febuxostat	NICE TAG 164	BNF 10.1.4
Collagenase Clostridium		BNF 10.3.1
histolyticum (Xiapex®)		
Capsaicin patch 8% (Qutenza <sup>®</sup> )		BNF 10.3.2

### Skin

LiquiBand <sup>®</sup>		BNF 13.10.5
------------------------	--	-------------

### **Anaesthesia**

Propofol-Lipuro®	BNF 15.1.1
Parecoxib	BNF 15.1.4
Rocuronium bromide	BNF 15.1.5
Sugammadex	BNF 15.1.6
Levobupivacaine	BNF 15.2
Lidocaine 4% (Laryngojet <sup>®</sup> )	BNF 15.2
Lidocaine 5% with phenylephrine 0.5%	BNF 15.2
Ropivacaine	BNF 15.2

Updated March 2013